Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab versus cisplatin with radiotherapy for HPV-positive oropharyngeal squamous cell carcinoma
ACTRN12613000279729Phase 3Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Jun 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in oropharyngeal squamous cell carcinoma (OPSCC) and oropharyngeal squamous cell carcinoma comparing Radiotherapy + cetuximab with Radiotherapy + cisplatin (2 arms). Primary endpoint: Area under the curve of symptom severity. Started Jun 2013; status: completed.
02
Drugs
cetuximabcisplatin
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)oropharyngeal squamous cell carcinoma
Beyond the preview
Go deeper on ACTRN12613000279729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000279729.